Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H U Group HoldingsTSE:4544 +1.32%69 EV-to-EBIT is 18.52 as of Aug. 23, 2026, which is 40% above its 10-year median of 13.25. GuruFocus rates TSE:4544 with a GF Score™ of 69/100 and a GF Value™ of 円2,844.16 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, H U Group Holdings ranks better than 60.95% on this metric.
The historical rank and industry rank for H U Group Holdings's EV-to-EBIT or its related term are showing as below:
TSE:4544'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1260.95 Med: 13.25 Max: 332.33
Current: 18.52
During the past 13 years, the highest EV-to-EBIT of H U Group Holdings was 332.33. The lowest was -1260.95. And the median was 13.25.
TSE:4544's EV-to-EBIT is ranked better than 60.95% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.29
vs TSE:4544: 18.52
H U Group Holdings (TSE:4544) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
H U Group Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was 円210,183 Mil.
H U Group Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円12,413 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H U Group Holdings EV-to-EBIT Related Terms
H U Group Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for H U Group Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, H U Group Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H U Group Holdings EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, H U Group Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where H U Group Holdings's EV-to-EBIT falls into.
H U Group Holdings's current Enterprise Value is 円229,881 Mil.
H U Group Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円12,413 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H U Group Holdings (TSE:4544) has a EV-to-EBIT of 18.52 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on H U Group Holdings and its competitors. This is 40% above median its historical median of 13.25. According to the industry distribution chart, H U Group Holdings ranks #41 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 39%.
Is H U Group Holdings' EV-to-EBIT too high?
H U Group Holdings' current EV-to-EBIT of 18.52 is 40% above median its 10-year median of 13.25. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.29. H U Group Holdings' value of 18.52 is 20.5% below this industry median. Based on the distribution chart, H U Group Holdings ranks #41 out of 105 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, H U Group Holdings has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does H U Group Holdings' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, H U Group Holdings ranks #41 out of 105 companies for EV-to-EBIT. This puts H U Group Holdings in the upper half of its industry. The industry median EV-to-EBIT is 23.29. H U Group Holdings' value of 18.52 is 20.5% below this benchmark. While the company's 10-year median is 13.25 vs. the industry median of 23.29, H U Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.29, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H U Group Holdings's current EV-to-EBIT of 18.52 is 20.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on H U Group Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H U Group Holdings's current EV-to-EBIT is 18.52, which is 40% above median its own 10-year median of 13.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H U Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, H U Group Holdings (TSE:4544) is currently considered Modestly Overvalued. The stock's GF Value™ is 円2,844.16, compared to a current price of 円3,680.00 — trading 29.4% above its estimated fair value. The current EV-to-EBIT is 18.52, which is 40% above median its 10-year median of 13.25 and 20.5% below the Medical Diagnostics & Research industry median of 23.29. H U Group Holdings' overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For H U Group Holdings (TSE:4544), the current EV-to-EBIT is 18.52 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H U Group Holdings (TSE:4544) Overvalued in 2026?
Based on GuruFocus' analysis, H U Group Holdings stock appears to be overvalued.
The current stock price of 円3,680.00 is trading 29.4% above its estimated GF Value™ of 円2,844.16.
GuruFocus considers H U Group Holdings to be Modestly Overvalued.
Key valuation signals for TSE:4544:
EV-to-EBIT: 18.52 (40% above median its 10-year median of 13.25)
GF Value™: 円2,844.16 vs. price of 円3,680.00 (29.4% above fair value)
Industry Position: 20.5% below the Medical Diagnostics & Research median (#41 of 105)
No single metric tells the full story. See the TSE:4544 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
H U Group Holdings Inc operates in the healthcare field, focusing on clinical laboratory testing and reagents. The company is engaged in four main businesses. The Clinical Laboratory Testing Business receives samples taken from patients at medical institutions to test for the disease and confirm the condition of the patient's health; In Vitro Diagnostics develops, manufactures, and sells testing reagents and equipment inside and outside Japan; Sterilization & Related Services Business provides a range of medical-related services including sterilization; and Emerging New Business & Others is a new business for future growth.
69GF Score
Get the complete analysis for TSE:4544
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4544 has been successfully added to your 
